Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Blood (2014) 124 (21): 723.

https://doi.org/10.1182/blood.V124.21.723.723

Published: 2014

Journal Articles

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

Blood (2014) 124 (21): 637.

https://doi.org/10.1182/blood.V124.21.637.637

Published: 2014

Journal Articles

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

Blood (2014) 124 (21): 640.

https://doi.org/10.1182/blood.V124.21.640.640

Published: 2014

Journal Articles

High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation

Martin F Kaiser, MD, Alexander Murison, PhD, Charlotte Pawlyn, MBBChir, Eileen M Boyle, MD, David C Johnson, PhD, Brian A Walker, PhD, Ping Wu, MBBS, MSc, Dil Begum, BSc, Nasrin Dahir, BSc, Christopher P Wardell, PhD, Paula Proszek, MSc, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 2189.

https://doi.org/10.1182/blood.V124.21.2189.2189

Published: 2014

Journal Articles

The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact

Blood (2014) 124 (21): 2194.

https://doi.org/10.1182/blood.V124.21.2194.2194

Published: 2014

Journal Articles

Myeloma XI Trial – Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients

John Jones, MD, Charlotte Pawlyn, MBBChir, Annamaria Brioli, David A Cairns, PhD, Ana Quartillo, Rachel Sigsworth, Helen Howard, PhD, Corinne Collett, Jacqueline Ouzman, PhD, Walter Gregory, PhD, Nigel Russell, Graham H Jackson, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 4744.

https://doi.org/10.1182/blood.V124.21.4744.4744

Published: 2014

Journal Articles

Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA

Martin F Kaiser, MD, Paula Proszek, MSc, Dil Begum, BSc, Nasrin Dahir, BSc, Brian A Walker, PhD, Suvi Savola, PhD, Eileen M Boyle, MD, David C Johnson, PhD, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2014) 124 (21): 5168.

https://doi.org/10.1182/blood.V124.21.5168.5168

Published: 2014

Journal Articles

High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients

Martin F Kaiser, MD, Eileen M Boyle, MD, Brian A Walker, PhD, Charlotte Pawlyn, MBBChir, Dil Begum, BSc, Paula Proszek, MSc, Nasrin Dahir, BSc, David C Johnson, PhD, Suvi Savola, PhD, David A Cairns, PhD, Walter Gregory, PhD, Graham Jackson, MD, Roger G Owen, MD, Gordon Cook, MD PhD, Mark T Drayson, MDPhD, Faith E Davies, MD, Gareth J. Morgan, MD PhD

Blood (2014) 124 (21): 172.

https://doi.org/10.1182/blood.V124.21.172.172

Published: 2014

Journal Articles

Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction

Andy C Rawstron, BSc, PhD, Walter Gregory, PhD, Ruth M de Tute, Faith E Davies, MD, Susan E Bell, DPhil, Mark T Drayson, MDPhD, Gordon Cook, MD, Graham H Jackson, MD, James A Child, Gareth J. Morgan, MD PhD, Roger G Owen

Blood (2014) 124 (21): 3416.

https://doi.org/10.1182/blood.V124.21.3416.3416

Published: 2014

Journal Articles

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Rowan Kuiper, BSc, Martin H. Van Vliet, PhD, Erik H. van Beers, PhD, Annemiek Broijl, MDPhD, George Mulligan, PhD, Hervé Avet-Loiseau, Walter Gregory, PhD, Gareth J. Morgan, MD PhD, Hartmut Goldschmidt, MD, Henk Lokhorst, MDPhD, Mark van Duin, PhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 3358.

https://doi.org/10.1182/blood.V124.21.3358.3358

Published: 2014

Journal Articles

Time to Next Treatment Is Response Dependent and Treatment Independent Based on Evidence from RCTs in Stem Cell Transplantation Eligible Multiple Myeloma Patients

Chrissy H. Y. Van Beurden-Tan, MSc, Philippe Moreau, MD, Laura Rosiñol, MD PhD, Walter Gregory, PhD, Michel van Agthoven, PhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 2122.

https://doi.org/10.1182/blood.V124.21.2122.2122

Published: 2014

Journal Articles

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

Blood (2013) 122 (21): 1847.

https://doi.org/10.1182/blood.V122.21.1847.1847

Published: 2013

Journal Articles

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Peter Hillmen, MB ChB, PhD, Donald Milligan, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, Lucy McParland, Anna Chalmers, Tahla Munir, MB ChB, Abraham M Varghese, MB ChB, Andy C Rawstron, BSc, PhD, David J Allsup, MD, PhD, Scott Marshall, MD, Alex Smith, BSc, Corinne Collett, Walter Gregory, PhD, Andrew Duncombe, MD, Dena Cohen, BSc, MSc

Blood (2013) 122 (21): 1639.

https://doi.org/10.1182/blood.V122.21.1639.1639

Published: 2013

Journal Articles

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

Annamaria Brioli, MD, John P. Campbell, PhD, Martin F Kaiser, MD, Charlotte Pawlyn, MD, Graham H. Jackson, MD, Walter Gregory, PhD, Roger G. Owen, MD, J. Anthony Child, MD, Faith E. Davies, MD, Michele Cavo, MD, Mark T. Drayson, MD PhD, Gareth J. Morgan, MD PhD

Blood (2013) 122 (21): 752.

https://doi.org/10.1182/blood.V122.21.752.752

Published: 2013

Journal Articles

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

Annamaria Brioli, MD, Charlotte Pawlyn, MD, Walter Gregory, PhD, Samantha Hinsley, MSc, Samantha Marshall, Jindriska Lindsay, MD, Claire Chapman, MD, Gordon Cook, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Michele Cavo, MD, Graham H Jackson, MD, Nigel Russel, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 2074.

https://doi.org/10.1182/blood.V122.21.2074.2074

Published: 2013

Journal Articles

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

Rowan Kuiper, Martin van Vliet, Annemiek Broyl, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari, George Mulligan, Walter Gregory, PhD, Gareth J Morgan, MD PhD, Hartmut Goldschmidt, MD, Uta Bertsch, MD, Henk Lokhorst, Mark van Duin, Erik van Beers, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3092.

https://doi.org/10.1182/blood.V122.21.3092.3092

Published: 2013

Journal Articles

A Rapid and Robust Molecular Diagnostic Approach For Multiple Myeloma – Results From a Large Trial Cohort

Martin F. Kaiser, MD, Dil Begum, BSc, Paula Proszek, MSc, Nasrin Dahir, BSc, David Gonzalez de Castro, PhD, Charlotte Pawlyn, MD, Annamaria Brioli, MD, Suvi Savola, PhD, Walter Gregory, PhD, Roger G. Owen, MD, Graham H. Jackson, MD, Faith E Davies, MD, Brian A Walker, PhD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 3097.

https://doi.org/10.1182/blood.V122.21.3097.3097

Published: 2013

Journal Articles

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Stephen A Schey, MD, Kwee L Yong, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, Faith E Davies, MD, Gareth J Morgan, MD PhD, James D. Cavenagh, MD, Gordon Cook, MD, PhD, Mark Cook, Avie-Lee Coney, Sarah Brown, PhD, Louise M Flanagan, PhD, Walter Gregory, PhD, Jim Cavet, FRCPath

Blood (2013) 122 (21): 286.

https://doi.org/10.1182/blood.V122.21.286.286

Published: 2013

Journal Articles

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

Charlotte Pawlyn, MD, Annamaria Brioli, MD, Walter Gregory, PhD, Samantha Hinsley, MSc, Jindriska Lindsay, MD, Gordon Cook, MD, PhD, Donald Milligan, MD, Claire Chapman, MD, Roger G Owen, MD, Mark T Drayson, MD PhD, Nigel Russell, MD, Graham H Jackson, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 540.

https://doi.org/10.1182/blood.V122.21.540.540

Published: 2013

Journal Articles

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Charlotte Pawlyn, MD, Lorenzo Melchor, PhD, Eileen M Boyle, MD, Annamaria Brioli, MD, Martin F Kaiser, MD, Walter Gregory, PhD, Mark T Drayson, MD PhD, Graham Jackson, MD, Fiona M Ross, DPhil, J. Anthony Child, MD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2013) 122 (21): 529.

https://doi.org/10.1182/blood.V122.21.529.529

Published: 2013

NARROW

Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation

The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact

Myeloma XI Trial – Second Primary Malignancy Interim Report in Newly Diagnosed Multiple Myeloma (NDMM) Patients

Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA

High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients

Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction

Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System

Time to Next Treatment Is Response Dependent and Treatment Independent Based on Evidence from RCTs in Stem Cell Transplantation Eligible Multiple Myeloma Patients

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Serum Free Light Chain Escape In Progression and Treatment Resistance In Multiple Myeloma: A Marker For The Impact Of Intra-Clonal Heterogeneity

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification

A Rapid and Robust Molecular Diagnostic Approach For Multiple Myeloma – Results From a Large Trial Cohort

Identifying An Optimally Effective But Tolerable Dose Of Bendamustine In Combination With Thalidomide and Dexamethasone In Patients With Relapsed Or Refractory Multiple Myeloma

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only